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Background: The UK’s National Institute for Health and Care Excellence (NICE) has recommended
contrast-enhanced ultrasound (CEUS) for the characterisation of focal liver lesions where the results of standard
unenhanced ultrasound are inconclusive. A further recommendation is for CEUS to replace other imaging
modalities. However, little is currently known about the diagnostic pathways in the National Health Service (NHS)
followed by patients with potential liver lesions. The aim of this study was to identify the diagnostic pathways for a
number of representative hospital trusts and record the clinicians’ views on patient experiences of these processes
through a series of semi-structured interviews with UK clinicians (radiologists and sonographers) (N = 7). This study
was undertaken in the broader context of a larger research project where the overarching research question is
focused on patient preferences for CEUS and other imaging modalities, and how these impact on patient quality
of life (QOL).
Results: The results from the semi-structured interviews with UK clinicians revealed that there is a great deal of
heterogeneity in diagnostic pathways followed by patients with potential liver lesions which differ both within and
between hospitals. In terms of the patient experience, the clinicians believed that a combination of the more
patient-friendly ultrasound process, and the fact that scan results are given to patients in 80-90% of cases on the
day, as well as the problems inherent to other scan modalities (claustrophobia, anxiety) would lead to patients
preferring ultrasound compared with other imaging modalities (CT or MR). However, current clinical practice means
that patient choice is virtually non-existent.
Conclusions: The significant variation in diagnostic pathways across the NHS will require further standardisation
through local agreements if contrast-enhanced ultrasound is to replace other imaging modalities in characterising
focal liver lesions in line with NICE Diagnostics Guidance. The gradual development of patient choice of modalities
may necessitate a change of practice in radiology processes.
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Contrast-enhanced ultrasound (CEUS) using SonoVue®
contrast agent (sulphur hexafluoride microbubbles) has
been shown to accurately differentiate between malig-
nant and benign focal liver lesions [1], characterise focal
liver lesions [2,3] and liver metastases [4]. Furthermore,
serious adverse events are very rare with this technology
and are usually mild [5,6].* Correspondence: adam.smith@york.ac.uk
York Health Economics Consortium Ltd. University of York, Market Square,
Heslington York, YO10 5NHUK
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reproduction in any medium, provided the orIn August 2012, the UK’s National Institute for Health
and Care Excellence (NICE) issued guidance on the use of
SonoVue® contrast agent for contrast-enhanced ultrasound
imaging of the liver [7]. The NICE guidance recommended
the use of SonoVue® for a number of diagnostic processes:
1) the characterisation of incidentally detected focal liver le-
sions in adults where an unenhanced ultrasound has been
inconclusive, and 2) in patients undergoing surveillance for
cirrhosis or metastatic disease for whom contrast-enhanced
(CE) computed tomography (CT) or magnetic resonance
imaging (MR) is not clinically appropriate, accessible or ac-
ceptable (to the patient). Furthermore, the latter is indicatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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an unenhanced US scan is unsatisfactory or inconclusive.
The NICE guidance suggests that CEUS may be used in
the diagnostic pathway to replace contrast-enhanced CT
(CECT) and contrast enhanced MR (CEMR). The NICE
guidance also suggests that CEUS could be used as a “triage
step” in order to minimise the use of these two technolo-
gies, however, the available data only allowed CEUS to be
included as a replacement for CECT and CEMR. The po-
tential diagnostic pathways for these two options are shown
in Figures 1 and 2. However, a scoping search identified
that little is currently known about the diagnostic pathways
that patients follow when undergoing unenhanced/en-
hanced imaging for focal liver lesions.
This study was undertaken in the broader context of
our role as an External Assessment Centre (EAC) for
the NICE Medical Technologies Evaluation Programme
(MTEP) along with the Regional Medical Physics
Department at the Freeman Hospital (Newcastle Upon
Tyne NHS Foundation Trust UK)a. The overarching re-
search question is focused on patient preferences for
CEUS and other imaging modalities, and how these im-
pact on patient QOL, based on the recommendations
for further research in the diagnostics guidance issued
by NICE [7]:
Research is recommended on patient preferences, and
their impact on quality of life, for contrast-enhancedFigure 1 Diagnostic pathway for liver imaging with contrast-enhance
CT/contrast-enhanced MR.ultrasound and other imaging modalities. Ideally such
research should compare all appropriate imaging mo-
dalities in the same patient group [Section 7, 7.2].
The results of this research will help inform the devel-
opment of a survey instrument to detail patient experi-
ences of imaging scans, as well as a discrete choice
experiment to capture patient preference. Therefore, the
aim of this study was to produce an overview of clinical
practice with regards to diagnostic scans for incidental
focal lesions (CEUS/CECT/CEMR). In particular, we
were interested in recording the diagnostic pathway
followed by the patient from the point of referral (by the
GP or as an inpatient or outpatient), through to the scan
appointment (and process), and outcome, as well as
detailing clinicians' views on their patients' experiences
of this process, and how this could impact on patients’
quality of life (QOL).
Methods
Sample
The study used purposive sampling in recruiting the
participants: Bracco SpA (Milan, Italy, manufacturer of
SonoVue®) provided a list of hospitals and UK clinicians
(radiologists and sonographers) that use SonoVue® and
who had consented for their details to be made available
to third parties. None of the clinicians were contacted be-
fore approval had been sought and provided by Bracco.d ultrasound as a replacement for contrast-enhanced
Figure 2 Diagnostic pathway for liver imaging with contrast-enhanced ultrasound as a triage test to reduce the use of
contrast-enhanced CT/contrast-enhanced MR.
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umes of SonoVue® used at their centres, of these, four
responded and were interviewed. A further three contacts
were provided by our partners at Newcastle Upon Tyne
NHS Foundation Trust. In total, seven interviews were
carried out. As this study was a service evaluation no re-
search ethics or NHS R & D approval was required
(http://www.hra.nhs.uk/).
Design
Semi-structured interviews were held with clinicians ei-
ther in person or over the telephone. Use was made of
the NICE Guidance (DG5) to identify pathways, diag-
nostic and referral processes associated with the scan-
ning modalities. Furthermore, a preliminary review of
the literature had been undertaken to identify questions
and concerns of patients undergoing scans (e.g. claustro-
phobia, adverse events). Both of these were employed to
develop a set of questions which was used to guide the
interviews with clinicians (Additional file 1). The inter-
views were scheduled to last an hour and were con-
ducted by two interviewers (AF, ABS). Detailed notes of
the interview were independently taken by both inter-
viewers, and were reviewed after the interview. Any
omissions and/or errors were corrected and a penulti-
mate draft of the interview was then transcribed. This
was sent to the clinician concerned for comments and
feedback.Results
A total of 7 interviews were held with senior clinicians
at consultant radiographer or radiologist grade, all of
whom had significant experience in using SonoVue®.
The clinicians were employed at different NHS trusts
across England (North East, East Anglia, West Yorkshire
and London). The interviews lasted on average around
30 minutes. The initial interviews tended to take slightly
longer as the interviewers familiarised themselves with
the questions (approximately 45 – 60 minutes).
There were large reported variations in clinical prac-
tice both within and between different hospitals and
NHS trusts, and there were differences (within hospitals)
between individual clinicians. For instance, some hospi-
tals / trusts had local clinical guidelines in place in terms
of referral and scanning pathways, for others, these deci-
sions were based on individual clinical judgement (see
Figure 3). This scenario is further complicated by the
fact that contrast-enhanced ultrasound scans may be
provided by sole clinicians or a team of clinicians and
not all clinicians are trained to use SonoVue.
The diagnostic pathway between and within hospitals
varied at several different points. Patients were referred
through the GP or as an inpatient/outpatient (including
those on screening programmes). Waiting times for a
CEUS or standard ultrasound (US) appointment varied
considerably across trusts from between 1–2 weeks to
6 weeks (maximum waiting period recommended by the
Hospital





Figure 3 The possible diagnostic pathways followed by patients.
Table 1 Summary length of time to receive results
Modality Lesion benign Lesion malignant
CE-US (SonoVue) -Immediate Varies considerably by hospital:
-Within 24 hours
if inpatient, or
-Less than 1 week
-Within 1 week, if
results sent to GP
-Between 2 – 8 weeks
MR/CT Varies considerably
(>than for CE-US)
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2 weeks, which corresponds to the UK median waiting
time for diagnostic scans [8]. Lengthier waiting times are
to be expected particularly for GP referrals, as the GP
would in most instances not know that a focal liver le-
sion was present. One clinician reported that patients
may also receive the CEUS on the same day as another
scan. The differences in wait times depended on several
factors, including: the availability of trained staff and
hospital process (some hospitals were willing to ‘absorb’
the cost of performing a CEUS while only charging for
the standard US that the patient had been referred for,
in hospitals that were not willing or able to do this the
patient was to be referred back to their practitioner).
The wait time for results also varied between and within
hospitals with many patients receiving their results im-
mediately. The majority of clinicians (5/7, 71%) reported
that patients would be informed of their results on the day
of the scan if the lesion was benign. These clinicians noted
that patients would not be informed immediately if the le-
sion was malignant. However, one clinician noted that pa-
tients would be told of a malignancy if in his/her opinion
the patient would be able to cope with this information.
Contrast-enhanced ultrasound is currently used to charac-
terise a known lesion or as a diagnostic process. The proced-
ure times were approximately the same across the scanning
modalities at around 20–30 minutes (as reported by all 7
clinicians). Patients were unlikely to experience more than
two of the scanning modalities (i.e. they tended to experi-
ence standard US plus one of the contrast enhanced investi-
gations) according to the clinicians interviewed.
Adverse reactions or side-effects to CEUS were virtually
nonexistent: one clinician reported the incidence of adversereactions as <0.1% (another clinician reported two cases in
10 years of practice; however, neither of these was attribut-
able to the ultrasound contrast agent). In contrast to this,
all clinicians (N = 7) noted that MR/CT may induce anxiety
and feelings of claustrophobia and the contrast agent used
in CT scans was associated with side effects, such as, a me-
tallic taste, the feeling of bladder incontinence, nausea and/
or a rash. An increased risk of an adverse reaction to the
contrast agent used in CEMR was reported compared to
that used in CEUS. Furthermore, the ultrasound scan
process was described as a more patient-friendly and infor-
mal process than CT or MR scans. The clinician would be
present in the room to talk to the patient during the
process and a friend or family member could be present.
Ultrasound was described as having a shortened referral
pathway waiting time with the majority of clinicians provid-
ing the results for benign cases immediately after the scan.
However, practice varied on this point with some clinicians
(N= 2) informing inpatients of the results 24–72 hours after
the scan, or sending the results back to the referrer (hospital
or GP). For MR/CT, patients did not receive their results
immediately. These were sent to the referring clinician intro-
ducing further delays (and potentially more anxiety) for the
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results (ultrasound) was reported to lead to less patient anx-
iety. Both of these results are features of CT and MR scans
which produce multiple and more detailed images than
ultrasound requiring more time to be reviewed.
Currently, patients do not have a choice of which
scanning modality they receive. This was based virtually
always on clinical judgment (although patients do have
the choice of refusing a scan). However, in an isolated
case a single patient was able to choose the scanning
modality (ultrasound) following a refusal to undergo
another MR scan.
Discussion
The clinicians reported significant heterogeneity between
and within hospital trusts in terms of the scan process with
the patient diagnostic pathway varying significantly. These
initial results from the semi-structured interviews suggest
that ultrasound has little impact on patient quality of life
QOL. In contrast to this, the MR/CT process (scanner) and
time to results may impact on QOL (e.g. anxiety), however,
this may be transient and will be influenced by the outcome
of the scan. The different processes across hospitals, as well
as the inherent problems with MR/CT (e.g. anxiety and
claustrophobia) are likely to impact on QOL, however the
ability to detect this is going to be negatively affected as any
impact on QOL may be overshadowed by the “noise” cre-
ated through the variation in clinical practice (diagnostic
accuracy and the actual outcome of the scan as a confound-
ing variable). The clinicians suggested that patients (if given
a choice) would prefer ultrasound as there are fewer symp-
toms/side-effects, and less anxiety induced by the clinical
process (results in most cases are provided at the time of
the scan) compared to the MR/CT scanners.
The NICE Guidance [7] document for SonoVue® suggests
that CEUS could be employed either as a replacement for
CECT or CEMR. The NICE guidance also suggests (but
does not include in its recommendations) that CEUS could
be used as a “triage step”. It appeared from the interviews
that, in practice, CEUS was being used as a triage step to
reduce the amount of CT or MR scans (i.e. it was not only
being used when a CT or MR was not clinically appropri-
ate, accessible or acceptable to the patient). The findings of
this study suggest that, given the heterogeneity in diagnos-
tic pathways apparent across hospitals, this may be difficult
to implement across the UK’s NHS without further stand-
ardisation of diagnostic pathways.
The study was potentially limited by the small sample
size, however, the clinicians interviewed were from Trusts
of various sizes, geographic locations and with varying prac-
tices and therefore should be representative of the range of
practices currently in place in the NHS. Furthermore, given
the seniority of those interviewed we were able to capture a
broader view of diagnostic imaging processes. However, itshould be noted as a further potential limitation that the
study only focused on the patient pathways for practitioners
with considerable experience of using the technology,
which may have introduced bias.
In terms of providing a basis for further research, the
results from the clinician interviews suggest patients’ ex-
periences of the imaging modalities will primarily be im-
pacted by the inherent differences between ultrasound
and MR/CT scans, including the scan experience and the
variations in diagnostic pathway. The clinicians interviewed
reported that CEUS has virtually no side-effects, has shorter
waiting times for appointments and the results can be pro-
vided to patients immediately in the majority of cases,
thereby reducing any anxiety. Furthermore, the ultrasound
process itself, in contrast to the other modalities, should
not induce any anxiety or claustrophobia. However, the in-
vestigation itself may be very stressful to patients who want
to be reassured their lesion is benign. It may therefore be
posited that any differences in patient experience and QOL
across the modalities would be explained by these facts
alone (and influenced by the outcome of the scan, which is
common across the modalities). In other words, all things
being equal, given a similar diagnostic outcome the patient
experience will be more positive for ultrasound compared
to the other modalities. These results will help inform the
development of a survey instrument to detail patient expe-
riences of ultrasound scans, as well as a discrete choice
experiment to capture patient preference.
Conclusions
There is a degree of heterogeneity in respect of diagnostic
pathways for the characterisation of focal liver lesions
meaning that any attempts to introduce contrast-enhanced
ultrasound as a replacement or triage step for other im-
aging modalities may require further standardisation.
Endnote
aThis part of the EAC is undertaking a prospective audit
detailing the incidence of incidental focal liver lesions.
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Additional file 1: Questions for Clinicians.
Abbreviations
CE: Contrast-enhanced; CECT: Contrast-enhanced computerised tomography;
CEMR: Contrast-enhanced magnetic resonance imaging; CEUS: Contrast-
enhanced ultrasound; CT: Computerised tomography; DG: Diagnostics
guidance; MTEP: Medical Technologies Evaluation Programme; QOL: Quality
of life; US: Ultrasound.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ABS, AF and LC designed the survey; ABS and AF conducted the interviews.
All authors contributed to the manuscript.
Smith et al. BMC Research Notes 2014, 7:199 Page 6 of 6
http://www.biomedcentral.com/1756-0500/7/199Acknowledgements
This study was funded through the NICE Medical Technologies Evaluation
Programme (MTEP). We are grateful to Dr Chris Pomfrett (MTEP) for
comments on an earlier draft of the manuscript, as well as comments from
our colleagues in the External Assessment Centre partnership at Newcastle
upon Tyne Hospitals NHS Foundation Trust (UK). Finally, the authors would
also like to thank the clinicians and ultrasound practitioners who took time
out of their work schedules for the interviews.
Received: 5 July 2013 Accepted: 21 March 2014
Published: 31 March 2014
References
1. Ooi CC, Low SC, Schneider-Kolsky M, Lombardo P, Lim SY, Abu Bakar R,
Lo RH: Diagnostic accuracy of contrast-enhanced ultrasound in
differentiating benign and malignant focal liver lesions: a retrospective
study. J Med Imaging Radiat Oncol 2010, 54(5):421–30.
2. Beaton C, Cochlin D, Kumar N: Contrast enhanced ultrasound should be
the initial radiological investigation to characterise focal liver lesions.
Eur J Surg Oncol 2010, 36(1):43–6.
3. Leen E, Angerson WJ, Yarmenitis S, Bongartz G, Blomley M, Del Maschio A,
Summaria V, Maresca G, Pezzoli C, Llull JB: Multi-centre clinical study
evaluating the efficacy of SonoVue (BR1), a new ultrasound contrast
agent in Doppler investigation of focal hepatic lesions. Eur J Radiol 2002,
41(3):200–6.
4. Albrecht T, Hohmann J, Oldenburg A, Skrok J, Wolf KJ: Detection and
characterisation of liver metastases. Eur Radiol 2004, 14(Suppl 8):P25–33.
5. Piscaglia F, Bolondi L, Italian Society for Ultrasound in Medicine and Biology
(SIUMB) Study Group on Ultrasound Contrast Agents: The safety of
Sonovue in abdominal applications: retrospective analysis of 23188
investigations. Ultrasound Med Biol 2006, 32(9):1369–75.
6. Torzilli G: Adverse effects associated with SonoVue use. Expert Opin Drug
Saf 2005, 4(3):399–401.
7. National Institute for Health and Clinical Excellence (NICE): SonoVue
(sulphur hexafluoride microbubbles) – contrast agent for







Cite this article as: Smith et al.: Heterogeneity in patient diagnostic
pathways: an example from contrast-enhanced ultrasound diagnostic
scans for focal liver lesions. BMC Research Notes 2014 7:199.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
